Andros Pharmaceuticals Co.,Ltd (TPEX: 6917)
Health Care · Pharmaceuticals · TW
NT$32.50
+1.72% today · +83.1% 1Y
Andros Pharmaceuticals Co.,Ltd (TPEX: 6917) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $46.31M and employs 15 people.
Over the last twelve months the share price has gained 83.1%, trading between 16.95 and 45.95.
6917 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $46.31M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- —
- Dividend yield
- —
- Beta (5Y)
- 0.54
- 52-week high
- NT$45.95
- 52-week low
- NT$16.95
- Avg volume (3M)
- —
- Shares outstanding
- 45.37M
- Employees
- 15
- Next earnings
- —
About Andros Pharmaceuticals Co.,Ltd
Andros Pharmaceuticals Co., Ltd. operates as a biopharmaceutical enterprise, concentrating on the advancement of novel drug delivery platform technologies. Its development pipeline features APC101, a metered-dose, quick-drying, film-forming spray undergoing Phase IIa clinical investigation for the management of pain linked to post-herpetic neuralgia. Also in development is APC201, an innovative topical anesthetic formulation currently in Phase I/II trials for Osteoarthritis treatment, alongside an siRNA (small interfering RNA) compound functioning as an antisense oligonucleotide and DNA candidate. In the preclinical phase, the company is advancing APC310 and APC501, both intended as anesthetics for intravenous catheter insertion and venipuncture. Another preclinical asset, APC401, is a specialized emulsified solution targeting post-surgical pain relief. Beyond its developmental programs, Andros Pharmaceuticals also provides LALP cream for dermal analgesic use, iMinos solution for treating Alopecia Androgenetica, and T4 endonuclease V. Established in 2008, the firm maintains its headquarters in Zhubei, Taiwan.
- ISIN
- TW0006917008
- Founded
- 2008
- Listed since
- Jan 12, 2023
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.